These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24626830)

  • 1. Reperfusion of large ischemic areas associated with central retinal vein occlusion: a potential novel treatment with activated protein C.
    Kamei M; Matsumura N; Suzuki M; Sakimoto S; Sakaguchi H; Nishida K
    JAMA Ophthalmol; 2014 Mar; 132(3):361-2. PubMed ID: 24626830
    [No Abstract]   [Full Text] [Related]  

  • 2. Reperfusion of areas of ischemia in central retinal vein occlusion.
    Tan CS; Chew MC; Sadda SR
    JAMA Ophthalmol; 2015 Feb; 133(2):227-8. PubMed ID: 25375959
    [No Abstract]   [Full Text] [Related]  

  • 3. Reperfusion of areas of ischemia in central retinal vein occlusion - reply.
    Kamei M; Nishida K
    JAMA Ophthalmol; 2015 Feb; 133(2):228-9. PubMed ID: 25375096
    [No Abstract]   [Full Text] [Related]  

  • 4. Activated Protein C for Ischemic Central Retinal Vein Occlusion: One-Year Results.
    Hara C; Kamei M; Sakaguchi H; Matsumura N; Sakimoto S; Suzuki M; Nishida K; Fukushima Y; Nishida K
    Ophthalmol Retina; 2019 Jan; 3(1):93-94. PubMed ID: 30935661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion.
    Udaondo P; Garcia-Delpech S; Salom D; Garcia-Pous M; Díaz-Llopis M
    Am J Ophthalmol; 2011 Aug; 152(2):326-7; author reply 327-8. PubMed ID: 21784203
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion.
    Sakuma T; Mizota A; Inoue J; Tanaka M
    Am J Ophthalmol; 2010 Dec; 150(6):876-82. PubMed ID: 20801424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction to the paper, "Peripheral areas of nonperfusion in treated central retinal vein occlusion as imaged by wide-field fluorescein angiography".
    Retina; 2014 May; 34(5):e15. PubMed ID: 25250422
    [No Abstract]   [Full Text] [Related]  

  • 8. Peripheral areas of nonperfusion in treated central retinal vein occlusion as imaged by wide-field fluorescein angiography.
    Spaide RF
    Retina; 2011 May; 31(5):829-37. PubMed ID: 21487338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal tissue plasminogen activator for acute central retinal vein occlusion.
    Lahey JM; Fong DS; Kearney J
    Ophthalmic Surg Lasers; 1999 Jun; 30(6):427-34. PubMed ID: 10392729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinal endovascular lysis in ischemic central retinal vein occlusion: one-year results of a pilot study.
    Feltgen N; Junker B; Agostini H; Hansen LL
    Ophthalmology; 2007 Apr; 114(4):716-23. PubMed ID: 17141322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion.
    Hattenbach LO; Friedrich Arndt C; Lerche R; Scharrer I; Baatz H; Margaron F; Richard G; Behrens-Baumann W; Ohrloff C
    Retina; 2009; 29(7):932-40. PubMed ID: 19584651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
    Chang LK; Spaide RF; Klancnik JM; Sorenson J; Slakter JS; Freund KB; Yannuzzi LA; Tseng JJ; Klein R
    Retina; 2011 May; 31(5):821-8. PubMed ID: 21317833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin(®) ).
    Algvere PV; Von Wendt G; Gudmundsson J; Seregard S; Kvanta A
    Acta Ophthalmol; 2010 Dec; 88(8):836-41. PubMed ID: 19900206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinal surgery for treatment of central retinal vein occlusion.
    Weiss JN
    Ophthalmic Surg Lasers; 2000; 31(2):162-5. PubMed ID: 10743932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.
    Ehlers JP; Decroos FC; Fekrat S
    Retina; 2011 Oct; 31(9):1856-62. PubMed ID: 21659943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinal endovascular lysis.
    Weiss JN
    Ophthalmology; 2008 Jan; 115(1):216-7; author reply 218. PubMed ID: 18166422
    [No Abstract]   [Full Text] [Related]  

  • 18. Intravitreal tissue plasminogen activator for the treatment of central retinal vein occlusion.
    Weizer JS; Fekrat S
    Ophthalmic Surg Lasers Imaging; 2003; 34(4):350-2. PubMed ID: 12875471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal and subretinal injection of tissue plasminogen activator (tPA) in the treatment of experimentally created retinal vein occlusion in rabbits.
    Ameri H; Kim JG; Ratanapakorn T; Chader GJ; Humayun MS
    Retina; 2008 Feb; 28(2):350-5. PubMed ID: 18301042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macular sensitivity and morphology after intravitreal injection of triamcinolone acetonide for macular edema with branch retinal vein occlusion.
    Noma H; Funatsu H; Mimura T; Shimada K
    Retina; 2012 Oct; 32(9):1844-52. PubMed ID: 22653545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.